FR2133979B1 - - Google Patents

Info

Publication number
FR2133979B1
FR2133979B1 FR7214052A FR7214052A FR2133979B1 FR 2133979 B1 FR2133979 B1 FR 2133979B1 FR 7214052 A FR7214052 A FR 7214052A FR 7214052 A FR7214052 A FR 7214052A FR 2133979 B1 FR2133979 B1 FR 2133979B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7214052A
Other languages
French (fr)
Other versions
FR2133979A1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of FR2133979A1 publication Critical patent/FR2133979A1/fr
Application granted granted Critical
Publication of FR2133979B1 publication Critical patent/FR2133979B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7214052A 1971-04-21 1972-04-20 Expired FR2133979B1 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13818671A 1971-04-21 1971-04-21
US13618671A 1971-04-21 1971-04-21

Publications (2)

Publication Number Publication Date
FR2133979A1 FR2133979A1 (enExample) 1972-12-01
FR2133979B1 true FR2133979B1 (enExample) 1975-10-31

Family

ID=26834087

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7214052A Expired FR2133979B1 (enExample) 1971-04-21 1972-04-20

Country Status (4)

Country Link
DE (1) DE2219408A1 (enExample)
FR (1) FR2133979B1 (enExample)
GB (1) GB1356763A (enExample)
NL (1) NL7204972A (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
CA2800618C (en) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN107141309A (zh) * 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
CN111944340B (zh) * 2020-08-21 2022-08-05 无锡市乐卡新材料有限公司 一种耐盐雾防锈涂料

Also Published As

Publication number Publication date
NL7204972A (enExample) 1972-10-24
DE2219408A1 (de) 1972-10-26
GB1356763A (en) 1974-06-12
FR2133979A1 (enExample) 1972-12-01

Similar Documents

Publication Publication Date Title
DE2246865C3 (enExample)
DK129844C (enExample)
DK138532C (enExample)
FR2134465A1 (enExample)
FR2133979A1 (enExample)
DE2257265B2 (enExample)
CS157132B2 (enExample)
CS152758B1 (enExample)
DE2106256C3 (enExample)
DE2126468C3 (enExample)
FR2090491A5 (enExample)
FI51394B (enExample)
CS170848B1 (enExample)
DK140005C (enExample)
FI47507B (enExample)
FR2121453B1 (enExample)
FI45697B (enExample)
DK139019C (enExample)
CS163444B1 (enExample)
CS156782B1 (enExample)
CS149148B1 (enExample)
CS167920B2 (enExample)
CS169853B1 (enExample)
CS149008B1 (enExample)
CS156271B1 (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse